Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2004
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2004
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    How should thyroid replacement be initiated?

    Landis, Suzanne E.
    Collins, Linda J.
    View/Open
    [PDF] HowShouldThyroidReplacement.pdf (84.04Kb)
    Date
    2004
    Format
    Article
    Metadata
    [+] Show full item record
    Abstract
    Levothyroxine (LT4) should be used alone as initial replacement for patients with hypothyroidism (strength of recommendation [SOR]: A). The optimal initial dose is 1.6 μg/kg/d for healthy people aged 60 years or younger (SOR: B). Patients aged more than 60 years may require less levothyroxine to achieve therapeutic serum thyroid hormone replacement, so initial replacement should be decreased to 25 to 50 μg daily (SOR: C). Since patients with known heart disease may develop dysrhythmias, angina, and myocardial infarctions when started on full replacement doses, experts recommend starting 12.5 to 25 μg daily for this population (SOR: C). Brand-name (Synthroid, Levoxyl, etc) and generic LT4 are bioequivalent (SOR: B), although the US Food and Drug Administration (FDA) does not consider these products to be interchangeable until proven therapeutically equivalent.
    URI
    http://hdl.handle.net/10355/3079
    Part of
    Journal of family practice, 53, no. 11 (November 2004): 925-926.
    Rights
    OpenAccess.
    This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
    Collections
    • Clinical Inquiries, 2004

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems